Polypeptide variants with altered effector function
First Claim
1. A polypeptide comprising a variant human IgG Fc region which is not a native sequence Fc region and has increased neonatal Fc receptor (FcRn) binding affinity, wherein the polypeptide comprises an amino acid modification at any one or more of amino acid positions 238, 256, 265, 272, 286, 303, 305, 307, 311, 312, 317, 340, 356, 360, 362, 376, 378, 380, 382, 413, 424, or 434 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.
0 Assignments
0 Petitions
Accused Products
Abstract
The present invention concerns polypeptides comprising a variant Fc region. More particularly, the present invention concerns Fc region-containing polypeptides that have altered effector function as a consequence of one or more amino acid modifications in the Fc region thereof.
-
Citations
18 Claims
- 1. A polypeptide comprising a variant human IgG Fc region which is not a native sequence Fc region and has increased neonatal Fc receptor (FcRn) binding affinity, wherein the polypeptide comprises an amino acid modification at any one or more of amino acid positions 238, 256, 265, 272, 286, 303, 305, 307, 311, 312, 317, 340, 356, 360, 362, 376, 378, 380, 382, 413, 424, or 434 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.
-
10. A polypeptide comprising a variant Fc region which is not a native sequence Fc region and has increased neonatal Fc receptor (FcRn) binding affinity, wherein the polypeptide comprises an amino acid modification at any one or more of amino acid positions 238, 256, 265, 272, 286, 303, 305, 307, 312, 317, 340, 356, 360, 362, 376, 378, 380, 382, 413, or 424 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.
- 11. A polypeptide comprising a variant Fc region which is not a native sequence Fc region and has increased neonatal Fc receptor (FcRn) binding affinity, wherein the polypeptide comprises amino acid substitutions at any two or more of amino acid positions 238, 256, 265, 272, 286, 303, 305, 307, 311, 312, 317, 340, 356, 360, 362, 376, 378, 380, 382, 413, 424, or 434 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.
-
14. A polypeptide comprising a variant Fc region which is not a native sequence Fc region and has increased neonatal Fc receptor (FcRn) binding affinity, wherein the polypeptide comprises substitutions at positions 307, 380 and 434 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.
-
15. An antibody that binds CD20 comprising a variant Fc region which is not a native sequence Fc region and has increased neonatal Fc receptor (FcRn) binding affinity, wherein the polypeptide comprises amino acid substitutions at any two or more of amino acid positions 238, 256, 265, 272, 286, 303, 305, 307, 311, 312, 317, 340, 356, 360, 362, 376, 378, 380, 382, 413, 424, or 434 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.
-
16. An antibody that binds vascular endothelial growth factor (VEGF) comprising a variant Fc region which is not a native sequence Fc region and has increased neonatal Fc receptor (FcRn) binding affinity, wherein the polypeptide comprises amino acid substitutions at any two or more of amino acid positions 238, 256, 265, 272, 286, 303, 305, 307, 311, 312, 317, 340, 356, 360, 362, 376, 378, 380, 382, 413, 424, or 434 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.
Specification